Drug safety is an important issue, especially in the experimental phases of development. Adverse immunostimulation (AI) is sometimes encountered following treatment with biopharmaceuticals, which can be life-threatening if it results in a severe systemic inflammatory reaction. Biopharmaceuticals that unexpectedly induce an inflammatory response still enter the clinic, even while meeting all regulatory requirements. Impurities (of microbial origin) in biopharmaceuticals are an often-overlooked cause of AI.
volunteers, even while meeting all criteria set forth by the applicable guidelines (see Box 2 and (Table 1 ).
Pichler proposed a classification specifically for biopharmaceuticals, which also categorized nonimmunotoxic adverse reactions (types δ and ε). Regarding immunopathological phenomena, type α reactions (termed "adverse immunostimulation" [AI] by the FDA) and hypersensitivity (type β), particularly anaphylaxis, are the most dangerous, for they can quickly become lethal.
Anaphylaxis and type α reactions have in common that unbalanced propagation of an immune reaction occurs with systemic release of various mediators, which ultimately leads to widespread organ dysfunction. [4] [5] [6] [7] In type α reactions, these mediators are cytokines, 3 resulting in a socalled cytokine storm. 6, 7 The source of these cytokines is the administration of (high doses of) cytokines or the release of cytokines following treatment with a biopharmaceutical. 3 This last category includes TGN1412, muromonab-CD3 and other monoclonal antibodies. [8] [9] [10] [11] Another, often overlooked, cause for cytokine release is the presence of impurities or contaminants within pharmaceuticals, typically of microbial origin, triggering an immune response.
It should be noted that a subtle difference exists between the original definition of type α reactions and AI:
in AI, high cytokine levels are not necessarily part of the pathogenesis, and AI can also include chronic inflammation. reactions and flu-like syndromes, which may refer to type α or type β reactions, or to both. 10, [12] [13] [14] For the sake of simplicity, the term "AI" is used throughout this article to describe acute, systemic, inflammatory reactions. It can be a matter of discussion whether these reactions may be classified as classical type α reactions. ) and all release criteria were met in terms of physical appearance, concentration and desired activity. Details on the impurity content and endotoxin levels are presented in Table 3 .
The single-dose toxicity of the drug substance was studied in rats and cynomolgus monkeys, up to a dose more than 10 times the highest dose ever administered to humans (allometrically scaled).
Repeated-dose toxicity studies were performed with the same dose levels in rats for up to 2 weeks, and in monkeys for up to 6 weeks.
Only effects that could be attributed to exaggerated pharmacology were observed, and those were completely reversible. No changes in behaviour, haematology or clinical chemistry occurred, and there were no relevant findings at autopsy.
Additionally, the pharmacodynamic activity of the drug, albeit from a different lot, had been studied in rabbits and in a mouse model of atherosclerosis. In this research, multiple animals died after repeated doses. The cause of these fatalities in mice was judged to be the induced cardiovascular disease. In rabbits, anaphylaxis developed, which was considered to be a response to repetitive exposure to a foreign protein.
In an unpublished phase I single-dose study in healthy volunteers (n = 28, five dose levels), X induced dose-dependent increases in the number of neutrophils, with a maximum at 4 hours postadministration. In addition, the incidence of gastrointestinal symptoms -occurring 2-4 hours after infusion -rose with each dose escalation, as did the incidence of diaphoresis and fever. 29 In the next phase, in patients with an acute coronary syndrome, 30 one patient out of a group of 22 receiving the highest dose level experienced what was described as a hypersensitivity reaction. A second (unpublished) patient trial was quickly suspended after one patient on active treatment developed a severe reaction during infusion, leading to multiorgan failure.
First step: Quality control
All parenterally administered pharmaceuticals have to conform to the requirements regarding sterility and endotoxin content, which are captured in the national, yet harmonized, pharmacopoeias. Sterility is considered proven by a negative culture result for a predefined fraction of the produced batch, usually after 14 days in a suitable medium.
For endotoxin, a margin of 5.0 IU per kg body weight per hour is internationally accepted ( Table 2 ). The limulus amoebocyte lysate assay is the preferred method for measuring endotoxin levels and has largely replaced the rabbit pyrogen test.
Biopharmaceuticals, such as X and Y, should be tested specifically for the presence of impurities. Residual cellular components of the manufacturing platform are recognized as potential triggers of the immune system, usually residual DNA and/or host cell proteins. Regulatory guidelines do not prescribe specific assays and acceptance criteria, but introduce a general concept of using validated, appropriate methods and setting (strict) upper limits, which need to be justified. 15 The exact battery of tests and criteria are reviewed and approved on a case-by-case basis by the regulatory authorities. Upon approval, these quality control measures are applied as release specification for individual batches of the drug product.
Second step: Safety pharmacology
For chemically derived compounds, an initial screen for potential immunotoxicity is mandatory, but this is not the case for biopharmaceuticals because they are target specific by design.
16,17
Indications for potential immunotoxicity are derived from animal experiments.
Relevant in vivo signs to detect AI include changes in (differential) leucocyte counts and globulin levels. Other useful parameters in assessing immune stimulation are part of the standard safety battery and include body temperature, heart rate and respiratory rate ( Table 2 ).
Third step: Clinical pharmacology
Specific tests for immunotoxicity in humans are not required, unless there is an indication that the drug candidate is potentially immunotoxic. Testing for immunogenicity by biopharmaceuticals is usually included because it is a known problem of this drug class. 18 Standard safety markers, such as haematology, clinical biochemistry, vital signs, as well as reports of adverse events, can be an indication of AI, provided that they are measured sufficiently frequently.
Important factors in the trial design to improve the safety of study participants include dose selection, entry criteria (eg, healthy volunteers vs patients), safety window and data monitoring committee. 19, 20 Later investigations demonstrated elevations in circulating interleukin (IL) 6 and tumour necrosis factor-alpha (TNF-α) levels following administration of X in humans, which were traced back to several host cell proteins (HCPs) within X, one of which was flagellin. 31, 32 The manufacturer required more than a decade to reduce or eliminate these
HCPs, but in the end X could be successfully reintroduced. Clinical studies with the new drug product confirmed the absence of any cytokine response both in healthy volunteers and patients. 33 ,34 b Notwithstanding pharmacopoeia monographs, a margin of 5.0 IU (or endotoxin unit, EU) per kg body weight per hour, or a dosing equivalent, is usually considered acceptable for parenterally administered products, with the exception of radiopharmaceuticals and intrathecally administered products, for which a lower limit is set. Respective European and US pharmacopoeias are not harmonized; they differ in the number of animals included in a retest, whether maximal individual temperature responses or summed responses are used, and the exact acceptance criteria.
d Only recommended for biopharmaceuticals.
e A limit of 10 ng per dose is commonly suggested, 27 although it is not absolute.
2,5
f Viral inactivation or removal is usually only tested on the cell line, not on the drug substance.
g Only required for marketing authorization, not for control of different batches (release specification).
h hA limit of 10 ng per dose is commonly suggested. were met, in terms of physical appearance, concentration and desired activity. Details on the impurity content and endotoxin levels are presented in Table 3 .
Toxicity was examined in rats and cynomolgus monkeys at a dose more than 10 times the highest dose ever administered to humans (allometrically scaled). Only single-dose toxicity studies were performed because the product was being developed as a one-dose treatment. No effects other than those expected to result from exaggerated pharmacology were detected.
In humans, dose-dependent increases in the incidence of gastrointestinal complaints and fever were observed following treatment with Y (single dose, n ≈ 10). The severity of the reaction correlated with the peak value for C-reactive protein and plasma cytokine levels (IL-6 and TNF-α). Subsequent analyses into the cause of the events revealed that Y caused toll-like receptor (TLR) 4-mediated activation, despite a negative limulus amoebocyte lysate (LAL) test. In addition, using a different method, >10% protein aggregates were detected in Y. It took more than 3 years to produce a new pharmacological-grade product with reduced levels of endotoxin, protein aggregates, residual DNA (rDNA) and host cell proteins. When the latter product was administered to healthy volunteers, no AI occurred at much higher plasma levels than were previously reached.
| THE WEAKEST LINK
These two cases raise the questions of how the causative impurities remained undetected, and why their immunostimulatory propensity was not recognized at an earlier stage, especially as the development was not marked by carelessness. On the contrary, the products were being manufactured by renowned companies, and studied and tested by dedicated scientists. The guidelines were meticulously followed, and more stringent than necessary acceptance criteria were applied (Tables 2 and 3 ). Yet, despite this, unforeseen AI occurred in the clinical studies. In the following paragraphs, we identify the most important shortcomings of the current testing strategy which allowed the culprits of AI in X and Y to escape detection in the preclinical phases of development.
| It's all in the number: Test sensitivity
Quality control is essentially based on using specific, validated methods for detecting unwanted components in pharmaceuticals.
However, all laboratory tests have their limitations and, in particular, insufficient sensitivity can be problematic. For example, Y met the endotoxin specification when tested with the LAL assay (Tables 2   and 3 ); yet, subsequent investigations demonstrated TLR4-mediated activation, and a specific endotoxin enzyme-linked immunosorbent assay (ELISA) indicated that actual levels were 10-20-fold higher than previously measured.
Although the definitive cause of the negative result in the LAL assay remains to be elucidated, it is known from the literature that the LAL assay cannot detect certain endotoxins, such as low-molecular-weight endotoxin. 35 The tests for other impurities can also give spuriously low results. Most commercially available assays for rDNA utilize an amplification technique which allows detection of only a selection of rDNA. 36 Likewise, assays for HCP quantification, typically ELISAs, measure only proteins against which antibodies were raised during the development of the assay, and do not capture other sources of contamination. 37, 38 The latter was the case with X, in which a process-specific ELISA measured an HCP concentration that was a factor of 3-4 higher than the initial result using a commercial, generic E. coli HCP ELISA.
| Behind the number: Potency
Specific, quantitative tests are routinely applied in quality control settings, as clear limits of acceptance can be defined. Although assays for Quantitative polymerase chain reaction.
tested impurities and contaminants seemingly provide black and white cut-offs, they are limited in predicting in vivo toxicity. For example, the LAL assay yields no information on the biological potency of a given endotoxin, which can differ between bacterial strains by a factor of 10,000. 39, 40 Additionally, a strict cut-off for one impurity does not take into account the potentially synergistic effects of multiple impurities. This is an important limitation as it is conceivable that multiple impurities are copurified at any given time during the production process. Both for X 32 and Y, it was not a single HCP or other bacterial product that could be identified as cause for the AI; it was the reduction in the total load of nonhuman material other than the pharmacologically active substance which resulted in the absence of AI in trial volunteers upon reintroduction into the clinic.
| Number and species: Animal toxicology
AI resulting from impurities can remain undetected in safety pharmacology studies as the relevant immunological pathway may not exist in the particular animal species or is different to that in humans. In addition, the sensitivity for bacterial products, such as endotoxin, can differ. 41 In particular, the relative lack of comparability between human and murine immune systems is noteworthy. 42, 43 However, the guidelines also call for short-term toxicity studies in a nonrodent species, in case a pharmacologically relevant nonrodent species exists. 16 Commonly, a primate is used for such studies with biopharmaceuticals. 44 Although the aforementioned factors may contribute to the failure to recognize AI, a subsequent investigation with X demonstrated that it elicited a cytokine response in cynomolgus monkeys similar to that in humans, with all the associated clinical features, such as fever, tachycardia and an increase in the white blood cell count. The real issue in this case therefore seems to be that either appropriately sensitive measures of AI (eg, circulating cytokines) had not been selected initially or that measurements had been taken too infrequently to detect AI (eg, vital parameters, haematology results).
| Blind spot
Surprisingly, testing for immunopathological effects is not included in the "Safety Pharmacology Core Battery", and in addition "routine test- Even when dedicated immunotoxicity studies are performed, the emphasis seems to be on long-term immunosuppression or enhancement by evaluating macroscopic pathology, organ weights and histology. 2, 17 This is at odds with the observation that undesired inflammatory reactions are commonly transient and rarely manifest themselves in histological changes. Case X highlights how the AI can be overlooked in safety pharmacology experiments as well as during clinical trials. AI in clinical trials may be easily misinterpreted as hypersensitivity or be grouped under a nonspecific term such as "infusion reaction".
| LESSONS FROM X AND Y
In the aftermath of the TGN1412 tragedy, an Expert Scientific Group made 22 recommendations to increase the safety of participants in (first-in-human) clinical trials. 46, 47 Many of these were reiterated following the more recent BIA 10-2474 trial disaster. 48, 49 The proposed risk assessments 46, 48, 50 focus on establishing the likelihood of unanticipated adverse effects of new drug substances entering the clinic, especially for those with complex and novel mechanisms. When applying this strategy to compounds X and Y, and specifically to (the novelty of) the mode of action and knowledge about human exposure to similar substances, it must be concluded that both X and Y were correctly labelled as safe.
The real threat to safety was the uncharacterized components in X and Y, impurities, the presence of which was not disputed (Table 3) , but the potential risk involved was underestimated. This line of reasoning is common, as is also apparent from the importance placed on dedicated immune toxicity studies in the international guidelines.
These are explicitly not recommended for biopharmaceuticals. 16 Furthermore, the immune system is regarded as being "of less immediate investigative concern" because it is an organ system, "the functions of which can be transiently disrupted by adverse pharmacodynamic effects without causing irreversible harm". and improve the sharing, of safety information. 46 Once more, the call by the scientific community for public release of the study results was heard in the days after the BIA 10-2474 trial, 49 ,51 yet remains to be fully answered. [54] [55] [56] [57] [58] Host cell impurities or microbial contamination have also been detected with cytokine release assays. 37, 52 The same was true for product X, which elicited an IL-6 and TNF-α response that was completely absent after the production process was modified. 29 By contrast, product Y induced no IL-6 or TNF-α release in any of the assays. As many variables can influence the read-out in these assays, and controversy still surrounds the interpretation of the results, cytokine release assays are currently only used as a tool for hazard identification of drug candidates that could induce AI. 58 Another strategy that has proven useful in detecting immunos- Despite the promising developments, no definitive answer to the best preclinical testing strategy can be given, as a fail-safe one probably does not exist. Every laboratory test has its limitations, can suffer from interference and can produce false-negative results, and with these a false sense of safety. Furthermore, the used expression platform, as well as physicochemical and pharmacological properties of the drug substance, each carries different risks of certain impurities being copurified, preventing the use of a general testing approach.
However, these limitations should not be used as an argument for maintaining the status quo. Undisputedly, the newer assays described above can detect far more causes of immunostimulation than the currently advised ones ( Table 2 ). Given the potential outcome of missing AI during early drug development, specific testing for AI should be part of performed toxicity studies for biopharmaceuticals, which is in sharp contrast with current guidelines.
It may be considered reassuring that, in retrospect, safety pharmacology studies in cynomolgus monkeys could have detected the immunostimulating propensity of X, provided that the right biomarkers were included. Likewise, signals of AI were observed early in the clinical trials with X and Y. Therefore, investigators should be on the alert for AI when studying biopharmaceuticals in animals and humans, especially if preclinical studies indicated that an IMP may elicit an inflammatory response. As always, a sentinel approach and a cautious dose escalation scheme with a prudently low starting dose should be applied in first-in-human trials. These measures will decrease the likelihood of (severe) AI in later stages, although such reactions can probably never be completely prevented.
Moreover, AIs should not be treated simply as rare idiosyncratic reactions that may be caused by a few biopharmaceuticals. They can severely disrupt vital organ systems, and in many cases indicative signs of AI were left for the discerning eye at some point during development. Awareness is thus probably the most important lesson to be learnt from case X and case Y. Equally important is the publication of cases of AI, to facilitate scientific discussion and improve drug safety.
